Penicillamine and Drugs With a Specific Action in Rheumatoid Arthritis

  • E. C. Huskisson
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 50 / 2)


For many years, the objective of much research into the drug treatment of rheumatic disease has been the development of better ways of suppressing inflammation. This approach has made little impact in rheumatoid arthritis (RA), a disease which appears to be more appropriately treated with specific drugs like D-penicillamine. Drugs of this type are not only more effective than anti-inflammatory drugs in RA but, with long-term therapy, they may alter the eventual outcome of the disease.


Rheumatoid Arthritis Systemic Lupus Erythematosus Adjuvant Arthritis Pertussis Vaccine Gold Salt 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arrigoni-Martelli, E., Bramm, E.: Investigations in the influence of cyclophosphamide, gold sodium thiomalate, and D-penicillamine on nystatin oedema and adjuvant arthritis. Agents Actions 5, 264–267(1975)CrossRefGoogle Scholar
  2. Arrigoni-Martelli, E., Bramm, E., Huskisson, E.C., Willoughby, D.A., Dieppe, P.A.: Pertussis vaccine oedema: an experimental model for the action of penicillamine-like drugs. Agents Actions 6, 613–617 (1976)PubMedCrossRefGoogle Scholar
  3. Aylward, M.: Clinical studies on alclofenac in the treatment of rheumatic diseases: a drug in question. Curr. med. Res. Opin. 3, 274–285 (1975)PubMedCrossRefGoogle Scholar
  4. Aylward, M., Davies, D.B.S.: A double-blind crossover trial comparing a new antirheumatic agent alclofenac with phenylbutazone in chronic rheumatic disorders. Brit. J. clin. Pract. 26, 517–521 (1972)Google Scholar
  5. Aylward, M., Parker, R.J., Maddock, J.: Studies on 4-alloxy-3 chlorophenylacetic acid (Alclofenac). Ann. rheum. Dis. 33, 268–272 (1974)PubMedCrossRefGoogle Scholar
  6. Berry, H., Huskisson, E.C. (1976) unpublished.Google Scholar
  7. Berry, H., Liyanage, S.P., Durance, R.A.: A controlled trial of penicillamine and azathioprine in the treatment of rheumatoid arthritis. Scand. J. Rheum. Suppl. 8, 21–26 (1975)Google Scholar
  8. Bluestone, R., Goldberg, L.S.: Effects of D-penicillamine on serum immunoglobulins and rheumatoid factor. Ann. rheum. Dis. 32, 50–52 (1973)PubMedCrossRefGoogle Scholar
  9. Brugmans J., Schuermans, Y., de Cock, W., Thienpont, D., Janssen, P., Verhaegen, H., Van Nimmen, L., Louwagie, A.C., Stevens, E.: Restoration of host defense mechanisms in man by Levamisole. Life Sci. 13, 1499–1504 (1973)PubMedCrossRefGoogle Scholar
  10. Camus, J.-P., Crouzet, J., Guillien, P., Benichou, C., Lievre, J.-A.: Cent cas de polyarthrite rhumatoide commune traites par la D-penicillamine. Ann. Med. interne (Paris) 125, 9–28 (1974)Google Scholar
  11. Cooperating Clinics Committee of the American Rheumatism Association: A controlled trial of cyclophosphamide in rheumatoid arthritis. New Engl. J. Med. 283, 883–889 (1970)CrossRefGoogle Scholar
  12. Currey, H.L.F., Harris, J., Mason, R.M., Woodland, J., Beveridge, T., Roberts, C.J., Vere, D.W., Dixon, A. St. J., Davies, J., Owen-Smith, B.: Comparison of azathioprine, cyclophosphamide and gold in the treatment of rheumatoid arthritis. Brit. med. J. III, 764–766 (1974)Google Scholar
  13. De Cree, J., Verhaegen, H., de Cook, H., Vanheule, R., Brugmans, J., Schuermans, V.: Impaired neutrophil phagocytosis. Lancet II, 294–295 (1974)CrossRefGoogle Scholar
  14. Dieppe, P.A., Willoughby, D.A., Huskisson, E.C., Arrigoni-Martelli, E.: Pertussis vaccine pleurisy: a model of delayed hypersensitivity. Agents Actions 6, 618–621 (1976)PubMedCrossRefGoogle Scholar
  15. Empire Rheumatism Council: Multicentre controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis. Ann. rheum. Dis. 16, 277–289 (1957)CrossRefGoogle Scholar
  16. Empire Rheumatism Council: Gold therapy in rheumatoid arthritis. Ann. rheum. Dis. 20, 315–340(1961)CrossRefGoogle Scholar
  17. Freedman, A.: Chloroquine and rheumatoid arthritis. Ann. rheum. Dis. 15, 251–257 (1956)PubMedCrossRefGoogle Scholar
  18. Freedman, A., Bach, F.: Mepacrine and rheumatoid arthritis. Lancet II, 321 (1952)CrossRefGoogle Scholar
  19. Freedman, A., Steinberg, V.L.: Chloroquine in rheumatoid arthritis. Ann. rheum. Dis. 19, 243–256 (1960)PubMedCrossRefGoogle Scholar
  20. Golding, J.R., Wilson, J.V., Day, A.T.: Observations on the treatment of rheumatoid arthritis with penicillamine. Postgrad, med. J. 46, 599–605 (1970)CrossRefGoogle Scholar
  21. Grahame, R., Billings, R., Laurence, M., Marks, V., Wood, P.J.: Tissue gold levels after chryso-therapy. Ann. rheum. Dis. 33, 536–539 (1974)PubMedCrossRefGoogle Scholar
  22. Herbert, C.M., Lindberg, K.A., Jackson, M.I.V., Bailey, A.J.: Biosynthesis and maturation of skin collagen in scleroderma and effect of D-penicillamine. Lancet I, 187–192 (1974)CrossRefGoogle Scholar
  23. Hirshaut, Y., Pinsky, C., Marquardt, H., Oettgen, H. F.: Effects of levamisole on delayed hypersen-sitivity reactions in cancer patients. 64 th meeting of the American Association for Cancer Research 14, 109 (1973)Google Scholar
  24. Hobbs, H.E., Sorsby, A., Freedman, A.: Retinopathy following chloroquine therapy. Lancet II, 478–480 (1959)CrossRefGoogle Scholar
  25. Hoebeke, J., Franchi, G.: Influence of tetramisole and its optical isomers on the mononuclear phagocytic system. J. reticuloendoth. Soc. 14, 317–323 (1973)Google Scholar
  26. Huskisson, E.C.: Recent drugs and the rheumatic diseases. Reports on Rheumatic Diseases 52, Arthritis and Rheumatism Council 1974Google Scholar
  27. Huskisson, E.C.: Penicillamine and the rheumatologist: a review. Pharmatherapeutica 1, 24–39 (1976)Google Scholar
  28. Huskisson, E.C., Berry, H.: Some immunological changes in rheumatoid arthritis among patients receiving penicillamine and gold. Postgrad, med. J. August suppl. 59–61 (1974)Google Scholar
  29. Huskisson, E.C., Dieppe, P.A., Scott, P.J., Trapnell, J.C., Balme, H.W., Willoughby, D.A.: Immuno-stimulant therapy for rheumatoid arthritis. Lancet I, 393–395 (1976a)CrossRefGoogle Scholar
  30. Huskisson, E.C., Gibson, T.J., Balme, H.W., Berry, H., Burry, H.C., Grahame, R., Hart, F.D., WojtulewskiJ.A.: Trial comparing D-penicillamine and gold in rheumatoid arthritis. Ann. rheum. Dis. 33, 532–535 (1974)PubMedCrossRefGoogle Scholar
  31. Huskisson, E.C., Hart, F.D.: Penicillamine in the treatment of rheumatoid arthritis. Ann. rheum. Dis. 31, 402–404 (1972)PubMedCrossRefGoogle Scholar
  32. Huskisson, E.C., Scott, P.J., Balme, H.W.: Objective measurement of rheumatoid arthritis using the technetium index. Ann. rheum. Dis. 35, 81–82 (1976 b)PubMedCrossRefGoogle Scholar
  33. Jaffe, I.A.: Intra-articular dissociation of the rheumatoid factor. J. Lab. clin. Med. 60, 409–421 (1962)PubMedGoogle Scholar
  34. Jaffe, I.A.: Comparisons of the effects of plasmapheresis and penicillamine on the level of circulating rheumatoid factor. Ann. rheum. Dis. 22, 71–76 (1963)PubMedCrossRefGoogle Scholar
  35. Jaffe, I.A.: The effects of penicillamine on the laboratory parameters in rheumatoid arthritis. Arthr. Rheum. 8, 1064–1079 (1965)CrossRefGoogle Scholar
  36. Jaffe, I.A.: Effects of penicillamine on the kidney and on taste. Postgrad, med. J. October suppl. 15–18(1968)Google Scholar
  37. Jaffe, I.A.: The treatment of rheumatoid arthritis and necrotizing vasculitis with penicillamine. Arthr. Rheum. 13, 435–443 (1970)CrossRefGoogle Scholar
  38. Jaffe, I.A., Merryman, P., Ehrenfeld, E.: Further studies of the anti-viral effect of D-penicillamine. Postgrad, med. J. August suppl. 50–55 (1974)Google Scholar
  39. Jessop, J.D., Vernon-Roberts, B., Harris, J.: Effects of gold salts and prednisolone on inflammatory cells. I. Phagocytic activity of macrophages and polymorphs in inflammatory exudates studied by a “skin-window” technique in rheumatoid and control patients. Ann. rheum. Dis. 32, 294–300(1973)PubMedCrossRefGoogle Scholar
  40. Joint Committee of the Medical Research Council and Nuffield Foundation: A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Ann. rheum. Dis. 19, 331–337 (1960)CrossRefGoogle Scholar
  41. Lima, A.O., Javierre, M.Q., da Silva, W.D., Camara, D.S.: Immunological phagocytosis: effects of drugs in phosphodiesterase activity. Experientia (Basel) 30, 945–946 (1974)CrossRefGoogle Scholar
  42. Liyanage, S.P., Currey, H.L.F.: Failure of oral D-penicillamine to modify adjuvant arthritis or immune response in the rat. Ann. rheum. Dis. 31, 521 (1972)PubMedCrossRefGoogle Scholar
  43. Maddock, J., Rees, P., Holly, F., Aylward, M.: The influence of alclofenac treatment on acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in patients with rheumatoid arthritis. Curr. med. Res. Opin. 3, 286–297 (1975)PubMedCrossRefGoogle Scholar
  44. Mowat, A., Huskisson, E.C.: D-Penicillamine in rheumatoid arthritis. Clin, rheum. Dis. 1, 319–333 (1975)Google Scholar
  45. Multicentre Trial Group: Controlled trial of D-penicillamine in severe rheumatoid arthritis. Lancet I, 275–280 (1973)CrossRefGoogle Scholar
  46. Ott, V.R., Schmidt, K.L.: Treatment of rheumatoid arthritis with D-penicillamine. Preliminary results of a controlled clinical trial. International Symposium on Penicillamine, 1974.Google Scholar
  47. Panayi, G.S., Neill, W.A., Duthie, J.J.R., McCormick, J.N.: Action of chloroquine phosphate in rheumatoid arthritis. I. Immunosuppressive effect. Ann. rheum. Dis. 32, 316–318 (1973)PubMedCrossRefGoogle Scholar
  48. Persellin, R.H., Ziff, M.: The effect of gold salt on lysosomal enzymes of the peritoneal macro-phage. Arthr. Rheum. 9, 57–65 (1966)CrossRefGoogle Scholar
  49. Popert, A.J., Meifers, K.A.E., Sharp, J., Bier, F.: Chloroquine diphosphate in rheumatoid arthritis. Ann. rheum. Dis. 20, 18–35 (1961)PubMedCrossRefGoogle Scholar
  50. Renoux, G., Renoux, M.: Effet immunostimulant d’un imidothiazol dans l’immunisation des souris contre l’infection par Brucella Abortus. C.R. Acad. Sci. (Paris) 272, 349–350 (1971)Google Scholar
  51. Renoux, G., Renoux, M.: Levamisole inhibits and cures a solid malignant tumour and its pulmonary metastases in mice. Nature (New Biol.) 240, 217–218 (1972 a)CrossRefGoogle Scholar
  52. Renoux, G., Renoux, M.: Inhibition par la theophylline de la stimulation immunologique induite par le phenylimidothiazole.C.R. Acad. Sci. (Paris) 274, 3149–3151 (1972 b)Google Scholar
  53. Roath, S., Willis, R.: The effects of penicillamine on lymphocytes in culture. Postgrad, med. J., August suppl. 56–67 (1974)Google Scholar
  54. Rothermich, N.D., Philips, V.K., Bergen, W., Thomas, M.H.: Excerpta Med. int. Congr. Ser. 299, 144(1973)Google Scholar
  55. Schuermans, Y.: Levamisole in rheumatoid arthritis. Lancet I, 111 (1975)CrossRefGoogle Scholar
  56. Schumacher, K., Maerker Alzer, G., Preuss, R.: Effect of D-penicillamine on lymphocyte function. Arzneimittel-Forsch. 25, 603–606 (1975)Google Scholar
  57. Sigler J.W., Bluhm, G.B., Duncan, H., Sharp, J.T., Gusign, D.C., McCrum, W.R.: Gold salts in the treatment of rheumatoid arthritis. A double-blind study. Ann. intern. Med. 80, 21–26 (1974)PubMedGoogle Scholar
  58. Stocker, E., Schairer, H.: D-penicillamine in juvenile rheumatoid arthritis. International Symposium on Penicillamine, 1974.Google Scholar
  59. Strong, J.S., Bartholomew, B.A., Smith, C.J.: Immunoresponsiveness of patients with rheumatoid arthritis receiving cyclophosphamide or gold salts. Ann. rheum. Dis. 32, 233–237 (1973)PubMedCrossRefGoogle Scholar
  60. Tripodi, D., Parks, L.C., Brugmans, J.: Drug-induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer. New Engl. J. Med. 289, 354–357 (1973)PubMedCrossRefGoogle Scholar
  61. Vernon-Roberts, B., Jessop, J.D., Dore, J.: Effects of gold salts and prednisolone on inflammatory cells. 2. Suppression of inflammation in the rat. Ann. rheum. Dis. 32, 301–307 (1973)PubMedCrossRefGoogle Scholar
  62. Vorenkamp, E.O., deBlecourt, J.J.: Gold treatment in rheumatoid arthritis. Abstr. VII Europ. Rheumat. Congr. 10, 1 (1971)Google Scholar
  63. Walz, D.T., Di Martino, M. J., Misher, A.: Suppression of adjuvant-induced arthritis in the rat by gold sodium. Ann. rheum. Dis. 30, 303–306 (1971)PubMedCrossRefGoogle Scholar
  64. Wiggins, L.F.: The chemical and biological background to alclofenac. Curr. med. Res. Opin. 3, 241–248 (1975)PubMedCrossRefGoogle Scholar
  65. Wright, V.: Rheumatism and psoriasis. Amer. J. Med. 27, 454–462 (1959)PubMedCrossRefGoogle Scholar
  66. Wyburn-Mason, R.: The significance of the effect of Clotrimazole on active rheumatoid disease. In: Abstracts of the 9 th International Congress of Chemotherapy 1974Google Scholar
  67. Yü, D.T.Y., Peter, J. B.: Cellular immunological aspects of “rheumatoid arthritis”. Semin. Arthr. Rheum. 4, 25–51(1974)CrossRefGoogle Scholar
  68. Zuckner, J., Ramsey, R.H., Dorner, R.W., Gantner, G.E.: D-penicillamine in rheumatoid arthritis. Arthr. Rheum. 13, 131–144 (1970)CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1979

Authors and Affiliations

  • E. C. Huskisson

There are no affiliations available

Personalised recommendations